Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1002/biof.1691

http://scihub22266oqcxt.onion/10.1002/biof.1691
suck pdf from google scholar
33249673!7744833!33249673
unlimited free pdf from europmc33249673    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid33249673      Biofactors 2021 ; 47 (1): 6-18
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Specialized proresolving mediators in infection and lung injury #MMPMID33249673
  • Sandhaus S; Swick AG
  • Biofactors 2021[Jan]; 47 (1): 6-18 PMID33249673show ga
  • Specialized proresolving mediators (SPMs) are endogenous lipid metabolites of long-chain polyunsaturated fatty acids that are involved in promoting the resolution of inflammation. Many disease conditions characterized by excessive inflammation have impaired or altered SPM biosynthesis, which may lead to chronic, unresolved inflammation. Exogenous administration of SPMs in infectious conditions has been shown to be effective at improving infection clearance and survival in preclinical models. SPMs have also shown tremendous promise in the context of inflammatory lung conditions, such as acute respiratory distress syndrome and chronic obstructive pulmonary disease, mostly in preclinical settings. To date, SPMs have not been studied in the context of the novel Coronavirus, severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), however their preclinical efficacy in combatting infections and improving acute respiratory distress suggest they may be a valuable resource in the fight against Coronavirus disease-19 (COVID-19). Overall, while the research on SPMs is still evolving, they may offer a novel therapeutic option for inflammatory conditions.
  • |*COVID-19 Drug Treatment[MESH]
  • |Anti-Inflammatory Agents/*therapeutic use[MESH]
  • |COVID-19/metabolism/pathology/virology[MESH]
  • |Docosahexaenoic Acids/*therapeutic use[MESH]
  • |Herpes Simplex/drug therapy/metabolism/pathology[MESH]
  • |Humans[MESH]
  • |Influenza, Human/drug therapy/metabolism/pathology[MESH]
  • |Lipoxins/*therapeutic use[MESH]
  • |Lung Injury/*drug therapy/metabolism/pathology/virology[MESH]
  • |Lung/drug effects/metabolism/pathology[MESH]
  • |Periodontitis/drug therapy/metabolism/pathology[MESH]
  • |Pulmonary Disease, Chronic Obstructive/*drug therapy/metabolism/pathology/virology[MESH]
  • |Respiratory Distress Syndrome/*drug therapy/metabolism/pathology/virology[MESH]
  • |SARS-CoV-2/pathogenicity[MESH]
  • |Sepsis/drug therapy/metabolism/pathology[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box